Eli Lilly has introduced new single-dose vials of its obesity medication Zepbound, priced at $399 for a four-week supply of 2.5mg doses and $549 for 5mg doses. This move aims to increase access and affordability for patients while ensuring the authenticity of the medication through LillyDirect, a self-pay platform that eliminates third-party involvement in the supply chain. The platform requires rigorous prescription verification, addressing concerns over the misuse of obesity drugs for cosmetic purposes and the proliferation of counterfeit products in the market.
The introduction of these vials also underscores Lilly's efforts to address supply shortages that have affected obesity medications globally. The company has been expanding its manufacturing capacity, with several sites ramping up or under construction, to meet the growing demand. This increased supply will be essential as Lilly plans to expand Zepbound's label to include treatment for obstructive sleep apnea, further broadening its potential patient base.
Lilly's initiative has been praised by the Obesity Action Coalition, which highlighted the company's leadership in promoting equitable care. The organization called on policymakers, employers, and insurers to collaborate with pharmaceutical companies like Lilly to ensure that all patients receive the care they need, emphasizing the importance of accessible and genuine treatment options in combating obesity.
Click here to read the original news story.